Teleflex Incorporated Introduces the UroLift 2 System With Advanced Tissue Control, a Revolutionary Unified Platform Designed to Treat All Prostate Types - Seite 2

“The UroLift 2 ATC is a game-changer. Bringing the enhanced tissue control capabilities onto the innovative and proven UroLift 2 platform allows me to deliver unparalleled precision to treat a broad spectrum of patients and anatomies. It has transformed my approach to BPH care,” said Dr. Adam Craig Thomas of Parkview Physicians Group Urology in Fort Wayne, Indiana.

Dr. Mark Pe with Genesis Urology in San Diego, California added, “I find it immensely helpful to have UroLift 2 ATC stocked and readily available at every procedure in case additional tissue control is needed. It ensures I’m always equipped to treat a broad range of patients with unique prostate types and anatomies.”

To learn more about UroLift 2 ATC, visit UroLift.com.

About the UroLift System
The UroLift System is a minimally invasive treatment for lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). It is indicated for the treatment of symptoms of an enlarged prostate up to 100cc in men 45 years or older (50 years outside U.S.). The UroLift System permanent implants, which can be delivered during an outpatient procedure,⁴ relieve prostate obstruction without heating, cutting, destruction of, or removing prostate tissue. The UroLift System can be used to treat a broad spectrum of anatomies, including obstructive median lobe.^5-6 It is the only leading BPH procedure shown to not cause new onset, sustained erectile or ejaculatory dysfunction.*^7-8 A study conducted over 5 years showed a low retreatment rate of about 2-3% per year, or a total of 13.6% over the course of the study, demonstrating UroLift System durability.¹ Most common side effects are temporary and can include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence.⁹ Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Individual results may vary. The prostatic urethral lift procedure (using the UroLift System) is recommended for the treatment of BPH in both the 2021 American Urological Association and 2022 European Association of Urology clinical guidelines. 475,000 men have been treated with the UroLift System in select markets worldwide.¹⁰ Learn more at www.UroLift.com. Rx only.